Professional Documents
Culture Documents
Oxford Handbook of
Rheumatology
Published and forthcoming Oxford Handbooks
Gavin Clunie
Consultant Rheumatologist and Metabolic Bone Physician,
Addenbrooke’s Hospital, Cambridge, UK
Nick Wilkinson
Consultant Paediatric and Adolescent Rheumatologist,
Evelina London Children’s Hospital, London, UK
Elena Nikiphorou
Consultant Rheumatologist, Whittington Hospital;
Clinical Researcher, Academic Rheumatology Department,
King’s College London, UK
Deepak Jadon
Consultant Rheumatologist and Director of the
Rheumatology Research Unit,
Addenbrooke’s Hospital, Cambridge, UK
1
1
Great Clarendon Street, Oxford, OX2 6DP,
United Kingdom
Oxford University Press is a department of the University of Oxford.
It furthers the University’s objective of excellence in research, scholarship,
and education by publishing worldwide. Oxford is a registered trade mark of
Oxford University Press in the UK and in certain other countries
© Oxford University Press 2018
The moral rights of the authors have been asserted
First Edition published in 2002
Second Edition published in 2006
Third Edition published in 2011
Fourth Edition published in 2018
Impression: 1
All rights reserved. No part of this publication may be reproduced, stored in
a retrieval system, or transmitted, in any form or by any means, without the
prior permission in writing of Oxford University Press, or as expressly permitted
by law, by licence or under terms agreed with the appropriate reprographics
rights organization. Enquiries concerning reproduction outside the scope of the
above should be sent to the Rights Department, Oxford University Press, at the
address above
You must not circulate this work in any other form
and you must impose this same condition on any acquirer
Published in the United States of America by Oxford University Press
198 Madison Avenue, New York, NY 10016, United States of America
British Library Cataloguing in Publication Data
Data available
Library of Congress Control Number: 2017960672
ISBN 978–0–19–872825–2
Printed and bound in China by
C&C Offset Printing Co., Ltd.
Oxford University Press makes no representation, express or implied, that the
drug dosages in this book are correct. Readers must therefore always check
the product information and clinical procedures with the most up-to-date
published product information and data sheets provided by the manufacturers
and the most recent codes of conduct and safety regulations. The authors and
the publishers do not accept responsibility or legal liability for any errors in the
text or for the misuse or misapplication of material in this work. Except where
otherwise stated, drug dosages and recommendations are for the non-pregnant
adult who is not breast-feeding
Links to third party websites are provided by Oxford in good faith and
for information only. Oxford disclaims any responsibility for the materials
contained in any third party website referenced in this work.
v
Foreword
Preface
Acknowledgements
The authors would like to acknowledge the work of the co-founder author-
editor of the textbook Dr Alan Hakim for his contribution, whom together
with Dr Clunie, devised and wrote the book from the first edition and co-
author-editor Dr Inam Haq (who joined for the 2nd and 3rd editions), in
helping to establish the Oxford Handbook of Rheumatology as the market
leader small textbook for rheumatology.
ix
Contents
Contributors xi
Symbols and abbreviations xii
Part II T
he clinical features and management
of rheumatic diseases
5 Rheumatoid arthritis 243
6 Osteoarthritis 265
7 Crystal-induced musculoskeletal disease 277
8 The spondyloarthritides including
psoriatic arthritis 293
9 Juvenile idiopathic arthritis 321
10 Systemic lupus erythematosus 343
11 Antiphospholipid syndrome 375
12 Sjögren’s syndrome 389
13 Systemic sclerosis and related disorders 401
14 Idiopathic inflammatory myopathies including
polymyositis and dermatomyositis 425
x CONTENTS
Index 729
xi
Contributors
E cross-reference
α alpha
β beta
i increased
d decreased
n normal
> greater than
< less than
7 approximately
∴ therefore
AAV ANCA-associated vasculitis
ABA abatacept
AC adhesive capsulitis
ACA anticentromere antibody
ACE angiotensin-converting enzyme
AChA acrodermatitis chronicum atrophicans
AC( J) acromioclavicular (joint)
ACL anticardiolipin
ACPA anticitrullinated peptide antibody(-ies)
ACR American College of Rheumatology
AD autosomal dominant
ADM abductor digiti minimi
AFF atypical femoral fracture
AICTD autoimmune connective tissue disease
AIS autoinflammatory syndrome
AKI acute kidney injury
ALNT anterolateral neospinothalamic tract
ALP alkaline phosphatase
ALT alanine transaminase
AMA amyloid A
AML amyloid L
ANA antinuclear antibody
ANCA antineutrophil cytoplasmic antibody
Anti-β2GP1 β2 glycoprotein-1
anti-
AOSD adult-onset Still’s disease
AP anteroposterior
SYMBOLS AND ABBREVIATIONS xiii
HMG-COA 3-hydroxy-3-methyl-glutaryl-coenzyme A
HPOA hypertrophic pulmonary osteoarthropathy
HPT hyperparathyroidism
HRT hormone replacement therapy
HSCT haematopoietic stem cell transplantation
HSP Henoch–Schönlein purpura
HUS haemolytic uraemic syndrome
HTLV human T-cell leukaemia virus
IA intra-articular
IBD inflammatory bowel disease
IBM inclusion-body myositis
ICD implantable cardioverter defibrillator
IFN interferon
IgG4-RD immunoglobulin G4-related disease
IGRA interferon gamma release assay
IIM idiopathic inflammatory myopathy
IL interleukin
ILAR International League of Associations for Rheumatology
ILD interstitial lung disease
IM intramuscular(ly)
IMM idiopathic inflammatory myopathy
INR international normalized ratio
IP interphalangeal
ISCD International Society of Clinical Densitometry
ISG International Study Group
ISN International Society for Nephrology
ITB iliotibial band
IV intravenous(ly)
IVDU intravenous drug user
IVIg intravenous immunoglobulin
JAK Janus kinase
JAS juvenile ankylosing spondylitis
JCA juvenile chronic arthritis
JDM juvenile dermatomyositis
JIA juvenile idiopathic arthritis
JIIM juvenile idiopathic inflammatory arthritis
JIO juvenile idiopathic osteoporosis
JPM juvenile polymyositis
JPsA juvenile psoriatic arthritis
JRA juvenile rheumatoid arthritis
xviii SYMBOLS AND ABBREVIATIONS
MPO myeloperoxidase
MR magnetic resonance
MRA magnetic resonance angiography
MRI magnetic resonance imaging
MSA myositis-specific autoantibodies
MSK musculoskeletal
MSU monosodium urate
MTP(J) metatarsophalangeal (joint)
MTX methotrexate
MUA manipulation under anaesthesia
MVA mevalonic aciduria
MVK mevalonate kinase
MWS Muckle–Wells syndrome
MYOACT myositis disease activity index
MYODAM myositis damage index
NAI non-accidental injury
NCS nerve conduction study
NICE National Institute for Health and Care Excellence (UK)
NLE neonatal lupus erythematosus
NLRs NOD-like receptors
NMS neuromuscular scoliosis
NO nitrous oxide
NOAC novel oral anticoagulant
NOD nucleotide-binding oligomerization domain
NOMID neonatal-onset multisystem inflammatory disease
NSAID non-steroidal anti-inflammatory drug
NSF nephrogenic systemic fibrosis
OA osteoarthritis
OI osteogenesis imperfecta
OMIN Online Mendelian Inheritance in Man
ONFH osteonecrosis of the femoral head
OO osteoid osteoma
OT occupational therapist
PAH pulmonary artery hypertension
PAMPS pathogen-associated molecular patterns
PAN polyarteritis nodosum
PAPA pyogenic arthritis, pyoderma gangrenosum, and acne
PBC primary biliary cirrhosis
PCR polymerase chain reaction
PDB Paget’s disease of bone
xx SYMBOLS AND ABBREVIATIONS
RTX rituximab
sACE serum angiotensin converting enzyme
SAI subacromial impingement
SAA serum amyloid A
SADAI Simplified Disease Activity Index
SAPHO synovitis, acne, palmoplantar pustulosis, hyperostosis,
aseptic osteomyelitis (syndrome)
SARA sexually acquired reactive arthritis
SC subcutaneous
SC(J) sternoclavicular (joint)
Scl systemic scleroderma
SCS spinal cord stimulation
SD standard deviation
sDMARD synthetic disease-modifying antirheumatic drug
SERM selective oestrogen receptor modulator
SHPT secondary hyperparathyroidism
SI( J) sacroiliac (joint)
SIP Sickness Impact Profile
SLE systemic lupus erythematosus
SLEDAI Systemic Lupus Erythematosus Disease Activity Index
SLICC Systemic Lupus International Collaborating criteria
SNRI serotonin-norepinephrine re-uptake inhibitors
SoJIA systemic-onset juvenile idiopathic arthritis
SpA spondyloarthritis
SRC scleroderma renal crisis
SRP signal recognition peptide
SS Sjögren’s syndrome
SScl systemic sclerosis
SSRI selective serotonin reuptake inhibitor
SSZ sulfasalazine
STIR short tau inversion recovery
SUA serum uric acid
SUFE slipped upper femoral epiphysis
T thoracic (e.g. T5 is the fifth thoracic vertebra)
TA Takayasu arteritis
TB tuberculosis
TCZ tocilizumab
TENS transcutaneous electrical nerve stimulation
TFT thyroid function test
TGF transferring growth factor
xxii SYMBOLS AND ABBREVIATIONS
The presentation
of rheumatic
disease
Chapter 1 3
Evaluating rheumatological
and musculoskeletal
symptoms
Introduction 4
Musculoskeletal pain in adults 6
Elicited pain on examination in adults 10
Other presenting symptoms in adults 12
The adult gait, arms, legs, spine (GALS) screening
examination 14
Pain assessment in children and adolescents 20
Limp and gait concerns in children and adolescents 22
Pyrexia, fatigue and unexplained acute-phase response
in children and adolescents 23
The paediatric GALS screen 24
4 Chapter 1 Evaluating MSK symptoms
Introduction
Adults and children can present with musculoskeletal (MSK), inflamma-
tory, and autoimmune diseases in varied ways. Symptoms can be simple
and focal, such as regional pain, or general and non-specific, often in the
context of a generalized process such as fever or fatigue. The following are
important points in assessing the time, type, and nature of presentation:
• Why someone has presented at a particular time.
• What is the impact of symptoms, emotionally and functionally.
• The individual’s perceptions, fears, or cultural references that might
modify (amplify or suppress) expression of the symptoms.
• What fears, beliefs, and factors might present a barrier to effective
medical engagement.
• The same pathological processes might present variably at different
ages: broadly speaking, the young, adults, and the elderly.
In this chapter, the assessment of symptoms has been separated into two
parts. First, the assessment of symptoms in adults and second, the patterns
of disease presentation in children and adolescents.
Introduction 5
6 Chapter 1 Evaluating MSK symptoms